SCHEMBL4864962

SCHEMBL4864962

CCN(c1ccc(F)cc1)C1(CNC(=O)N2CCCCc3ccccc32)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 4/20 0.48
TP53 P04637 1/20 0.46
AVPR1A P37288 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
POLB P06746 2/20 0.42
HSD11B1 P28845 1/20 0.42
MAPT P10636 1/20 0.42
OXTR P30559 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870861 0.80 AVPR2 (0.49) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4870765 0.80 AVPR2 (0.54) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4863033 0.79 AVPR2 (0.48) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4869509 0.79 AVPR2 (0.52) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4869441 0.77 TP53 (0.61) AVPR2TP53MEN1KMT2ALMNA
SCHEMBL4861652 0.76 TP53 (0.47) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4870809 0.76 TP53 (0.47) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4866912 0.76 AVPR2 (0.56) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4867148 0.75 POLB (0.48) AVPR2TP53AVPR1AMEN1KMT2A
SCHEMBL4867654 0.75 POLB (0.48) AVPR2TP53AVPR1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 AVPR2 124/4885TP53 4170/4885AVPR1A 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.